Table 4.
Subgroup Analyses of odds Ratios for ureteral stent related urinary symtoms (USSQ urinary symptom score) and ureteral stent related pain (USSQ-body pain score) in the two Groups.
| Subgroup | No. of patients | Placebo | Naftopidil | Odds ratio (95% CI) |
| USSQ urinary symptom score | ||||
| All patients | 92 | 30.90 ± 7.60 | 29.23 ± 7.66 | 0.760 (0.334–1.729) |
| Age | ||||
| <50 yr | 36 | 30.00 ± 7.22 | 30.07 ± 6.72 | 1.039 (0.275–3.919) |
| ≥50 yr | 56 | 31.57 ± 7.93 | 28.79 ± 8.20 | 0.647 (0.224–1.868) |
| Stone size | ||||
| <10 mm | 52 | 30.39 ± 7.56 | 28.26 ± 6.99 | 0.700 (0.220–2.226) |
| ≥10 mm | 40 | 31.94 ± 7.82 | 30.00 ± 8.22 | 0.600 (0.165–2.180) |
| Stone position | ||||
| Kidney | 44 | 32.67 ± 9.01 | 29.35 ± 8.48 | 0.385 (0.113–1.310) |
| Ureter | 48 | 29.57 ± 6.19 | 29.10 ± 6.81 | 1.264 (0.395–4.043) |
| Preoperative IPSS | ||||
| <12 | 62 | 29.85 ± 6.97 | 27.79 ± 7.23 | 0.649 (0.235–1.790) |
| ≥12 | 30 | 33.06 ± 8.59 | 32.21 ± 7.92 | 1.037 (0.244–4.411) |
| Surgery type | ||||
| RIRS with UAS | 47 | 32.82 ± 8.75 | 29.84 ± 8.36 | 0.431 (0.131–1.419) |
| Others | 45 | 29.33 ± 6.25 | 28.39 ± 6.71 | 1.082 (0.317–3.694) |
| Duration of ureteral stent | ||||
| <10 | 42 | 30.17 ± 7.09 | 27.90 ± 6.95 | 0.625 (0.170–2.291) |
| ≥10 | 50 | 31.69 ± 7.45 | 30.43 ± 8.44 | 0.894 (0.290–2.757) |
| USSQ body pain score | ||||
| All patients | 92 | 22.28 ± 12.26 | 19.58 ± 11.75 | 0.691 (0.303–1.577) |
| Age | ||||
| <50yr | 36 | 25.02 ± 13.78 | 23.40 ± 13.03 | 1.039 (0.275–3.919) |
| ≥50 yr | 56 | 20.21 ± 10.76 | 17.54 ± 10.69 | 0.556 (0.190–1.621) |
| Stone size | ||||
| <10 mm | 52 | 20.95 ± 12.95 | 19.84 ± 12.44 | 0.873 (0.279–2.728) |
| ≥10 mm | 40 | 25.00 ± 10.53 | 19.38 ± 11.44 | 0.429 (0.117–1.568) |
| Stone position | ||||
| Kidney | 44 | 24.19 ± 12.32 | 21.57 ± 13.37 | 0.385 (0.113–1.310) |
| Ureter | 48 | 20.84 ± 12.22 | 17.30 ± 9.37 | 1.030 (0.319–3.329) |
| Preoperative IPSS | ||||
| <12 | 62 | 21.11 ± 11.48 | 17.90 ± 12.88 | 0.495 (0.178–1.382) |
| ≥12 | 30 | 24.69 ± 13.78 | 23.07 ± 8.33 | 1.333 (0.315–5.642) |
| Surgery type | ||||
| RIRS with UAS | 47 | 24.43 ± 12.06 | 21.56 ± 12.80 | 0.850 (0.243–2.976) |
| Others | 45 | 20.52 ± 12.35 | 16.83 ± 9.79 | 0.431 (0.131–0.891) |
| Duration of ureteral stent | ||||
| <10 days | 42 | 21.50 ± 12.44 | 18.10 ± 13.22 | 0.500 (0.133–1.885) |
| ≥10 days | 50 | 22.91 ± 11.56 | 20.67 ± 10.39 | 0.894 (0.290–2.757) |
USSQ, Ureteral stent symptom questionnaire; IPSS, international prostate symptom score; RIRS, retrograde intrarenal surgery; UAS, ureteral access sheath.